Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. (SNSE) priced its initial public offering on Feb 4, 2021 at $19.00 per share, above its $16.00–$18.00 range, raising $133M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $561.6M. Citigroup was lead-left underwriter, joined by Piper Sandler and Oppenheimer. Cooley advised the company and Goodwin Procter advised the underwriters.

At its 2021 IPO, Sensei Biotherapeutics (now Faeth Therapeutics) was a clinical-stage immunotherapy company, initially focused on cancer, developing its ImmunoPhage platform, which uses bacteriophage to induce an innate and adaptive immune response.

Status

IPO

Ticker

SNSE

Exchange

Nasdaq Global Market

Priced

Feb 4, 2021

IPO price

$19.00

Price range

$16.00–$18.00

Raised

$133M

Market cap at IPO price

$561.6M

First filed

Jan 15, 2021

Underwriters

Citigroup, Piper Sandler and Oppenheimer

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.